A Recombinant Acetylcholine Receptor α1 Subunit Extracellular Domain Is a Promising New Drug Candidate for Treatment Of Myasthenia Gravis

A Recombinant Acetylcholine Receptor α1 Subunit Extracellular Domain Is a Promising New Drug Candidate for Treatment Of Myasthenia Gravis

Background and AimsMyasthenia gravis (MG) is a T-cell dependent antibody-mediated autoimmune disease in which the nicotinic acetylcholine receptor (AChR) is the major autoantigen, comprising several T and B cell auto-epitopes. We hypothesized that an efficacious drug candidate for antigen-specific t...

Full description

Bibliographic Details
Main Authors: Konstantinos Lazaridis, Maria Fernandez-Santoscoy, Vasiliki Baltatzidou, Jan-Olof Andersson, Richard Christison, John Grünberg, Socrates Tzartos, Björn Löwenadler, Charlotte Fribert
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Immunology
Subjects:
myasthenia gravis
acetylcholine receptor
autoimmune disease
antigen-specific immune tolerance
tolerogen
intravenous administration
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.809106/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.809106/full

Similar Items